Plague vaccine patent by iBio clears opposition period

Bio-tech company iBio Inc. received a notice from the European Patent Office that said the opposition period has passed on an iBio plague vaccine patent, the company said on Monday.

The vaccine uses antigens against Yersinia pestis to prevent the bacteria from infecting an individual. There is currently no vaccine approved in the U.S. against the plague. The same bacteria that caused the bubonic plague in medieval Europe is considered a Category A disease by the Centers for Disease Control and Prevention and is considered a threat to national security as a bio weapon.

The company was successful in applying to develop a combination vaccine that would protect against plague and anthrax infection. The success of this announcement allows the company to expand commercialization and development.

"We expect our success with vaccine and therapeutic product candidates for use against serious infectious disease agents with weapon potential, such as plague bacillus, to be of interest to governments and companies engaged in supplying disease countermeasures," iBio President Robert Erwin said.

The company has a vaccine candidate for anthrax currently in Phase I of clinical trials, and it has therapeutic antibodies for the influenza, Ebola and respiratory syncytial viruses.

Organizations in this Story

U.S. Centers for Disease Control and Prevention

Want to get notified whenever we write about U.S. Centers for Disease Control and Prevention ?
Next time we write about U.S. Centers for Disease Control and Prevention, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.